| A theranostic approach of [68Ga]Ga-DOTA.SA.FAPi PET/CT-guided [177Lu]Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: new … S Ballal, MP Yadav, V Kramer, ES Moon, F Roesch, M Tripathi, S Mallick, ... European journal of nuclear medicine and molecular imaging 48, 942-944, 2021 | 103 | 2021 |
| Biodistribution, pharmacokinetics, dosimetry of [68Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [18F]F-FDG PET/CT in patients with various cancers S Ballal, MP Yadav, ES Moon, VS Kramer, F Roesch, S Kumari, M Tripathi, ... European journal of nuclear medicine and molecular imaging 48, 1915-1931, 2021 | 101 | 2021 |
| Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators ES Moon, F Elvas, G Vliegen, S De Lombaerde, C Vangestel, ... EJNMMI radiopharmacy and chemistry 5, 1-20, 2020 | 75 | 2020 |
| Novel fibroblast activation protein inhibitor-based targeted theranostics for radioiodine-refractory differentiated thyroid cancer patients: a pilot study S Ballal, MP Yadav, ES Moon, F Roesch, S Kumari, S Agarwal, M Tripathi, ... Thyroid 32 (1), 65-77, 2022 | 64 | 2022 |
| First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [177Lu]Lu-DOTA.SA.FAPi and [177Lu]Lu-DOTAGA.(SA.FAPi)2 S Ballal, MP Yadav, ES Moon, VS Kramer, F Roesch, S Kumari, C Bal Pharmaceuticals 14 (12), 1212, 2021 | 63 | 2021 |
| New frontiers in cancer imaging and therapy based on radiolabeled fibroblast activation protein inhibitors: a rational review and current progress S Imlimthan, ES Moon, H Rathke, A Afshar-Oromieh, F Rösch, ... Pharmaceuticals 14 (10), 1023, 2021 | 42 | 2021 |
| Fibroblast activation protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: a step to improve tumor uptake and retention time ES Moon, S Ballal, MP Yadav, C Bal, Y Van Rymenant, S Stephan, ... American journal of nuclear medicine and molecular imaging 11 (6), 476, 2021 | 38 | 2021 |
| Squaric acid-based radiopharmaceuticals for tumor imaging and therapy T Grus, H Lahnif, B Klasen, ES Moon, L Greifenstein, F Roesch Bioconjugate Chemistry 32 (7), 1223-1231, 2021 | 23 | 2021 |
| 68Ga, 44Sc and 177Lu-labeled AAZTA5-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues JP Sinnes, U Bauder-Wüst, M Schäfer, ES Moon, K Kopka, F Rösch EJNMMI radiopharmacy and chemistry 5, 1-11, 2020 | 23 | 2020 |
| [68Ga] Ga-DATA5m. SA. FAPi PET/CT: specific tracer-uptake in focal nodular hyperplasia and potential role in liver tumor imaging B Kreppel, FC Gärtner, M Marinova, U Attenberger, M Meisenheimer, ... Nuklearmedizin-NuclearMedicine 59 (05), 387-389, 2020 | 18 | 2020 |
| First-in-human experience with 177Lu-DOTAGA.(SA. FAPi) 2 therapy in an uncommon case of aggressive medullary thyroid carcinoma clinically mimicking as anaplastic thyroid cancer S Ballal, MP Yadav, ES Moon, F Rösch, ST ArunRaj, S Agarwal, ... Clinical Nuclear Medicine 47 (6), e444-e445, 2022 | 15 | 2022 |
| Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET/CT correlates with Ki-67 in liver metastases of neuroendocrine tumours B Kreppel, MA Gonzalez-Carmona, G Feldmann, J Küppers, ES Moon, ... Nuklearmedizin-NuclearMedicine 60 (05), 344-354, 2021 | 14 | 2021 |
| In Vitro Evaluation of the Squaramide-Conjugated Fibroblast Activation Protein Inhibitor-Based Agents AAZTA5.SA.FAPi and DOTA.SA.FAPi ES Moon, Y Van Rymenant, S Battan, J De Loose, A Bracke, ... Molecules 26 (12), 3482, 2021 | 14 | 2021 |
| From Automated Synthesis to In Vivo Application in Multiple Types of Cancer—Clinical Results with [68Ga]Ga-DATA5m.SA.FAPi L Greifenstein, CS Kramer, ES Moon, F Rösch, A Klega, C Landvogt, ... Pharmaceuticals 15 (8), 1000, 2022 | 13 | 2022 |
| AAZTA5-squaramide ester competing with DOTA-, DTPA-and CHX-A ″-DTPA-analogues: Promising tool for 177Lu-labeling of monoclonal antibodies under mild conditions B Klasen, ES Moon, F Rösch Nuclear Medicine and Biology 96, 80-93, 2021 | 10 | 2021 |
| Effect of the versatile bifunctional chelator AAZTA5 on the radiometal labelling properties and the in vitro performance of a gastrin releasing peptide receptor … M Hofstetter, ES Moon, F D’Angelo, L Geissbühler, I Alberts, ... EJNMMI radiopharmacy and chemistry 5, 1-19, 2020 | 8 | 2020 |
| Impact of prompt gamma emission of 44Sc on quantification in preclinical and clinical PET systems F Rosar, H Bohnenberger, ES Moon, F Rösch, A Denig, D Vincenz-Zörner, ... Applied Radiation and Isotopes 170, 109599, 2021 | 7 | 2021 |
| Therapeutic potential of [177Lu]Lu-DOTAGA-FAPi dimers in metastatic breast cancer patients with limited treatment options: efficacy and safety assessment MP Yadav, S Ballal, M Martin, F Roesch, S Satapathy, ES Moon, ... European Journal of Nuclear Medicine and Molecular Imaging 51 (3), 805-819, 2024 | 5 | 2024 |
| Inhibition of Poly(ADP-ribose) Polymerase Sensitizes [177Lu]Lu-DOTAGA.(SA.FAPi)2-Mediated Radiotherapy in Triple-Negative Breast Cancer G Bao, H Zhou, S Zou, L Chen, B Zhang, Z Wang, ES Moon, J Zhao, ... Molecular Pharmaceutics 20 (5), 2443-2451, 2023 | 5 | 2023 |
| Head-to-head comparison of [68Ga]Ga-DOTA.SA.FAPi with [18F]F-FDG PET/CT in radioiodine-resistant follicular-cell derived thyroid cancers S Ballal, MP Yadav, F Roesch, S Satapathy, ES Moon, M Martin, ... European Journal of Nuclear Medicine and Molecular Imaging 51 (1), 233-244, 2023 | 4 | 2023 |
